ArticleDiscover oncology2025
Piezo1 regulates actin cytoskeleton remodeling to drive EMT in cervical cancer through the RhoA/ROCK1/PIP2 signaling pathway.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Piezo-type mechanosensitive ion channel component 1: a mechano-bioenergetic transducer in the tumour microenvironment.Annals of medicine · 2026Review
- Engineering Piezo1-Mediated Calcium Signalling for Enhanced Extracellular Vesicle Biogenesis and Cargo Loading.Journal of extracellular biology · 2026Article
- Piezo1 channel: structure, mechanogating mechanism, functions, diseases and therapeutic strategy.Molecular biomedicine · 2026Review
- The Dual Role of Piezo1 in Cancer: Mechanotransduction, Microenvironment Remodelling, and Therapeutic Opportunities.Drug design, development and therapy · 2026Review
- The Mechanosensation-Metabolism-Inflammation Axis: The Central Role of Piezo1 and TRPV4 in Hypertension-Related Atherosclerosis.International journal of general medicine · 2026Review
- Piezo1 promotes EMT and tumor progression in HNSCC through a YAP1-Associated Galectin-1 axis.Frontiers in cell and developmental biology · 2026Article
- Squishing, squeezing and stretching age hematopoietic stem cells.Nature aging · 2026Article
- A 'Spicy' Mechanotransduction Switch: Capsaicin-Activated TRPV1 Receptor Modulates Osteosarcoma Cell Behavior and Drug Sensitivity.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPiezo1 has been identified as an oncogenic factor in various types of cancer. The objective of this study was to explore the mechanisms of Piezo1 in cervical cancer invasion and migration, with a focus on its influence on actin cytoskeleton remodeling.
methodsImmunohistochemistry, western blot, and dot blot assays were employed to evaluate the expression levels of Piezo1, PIP2, and F-actin in cervical cancer. Lentiviral transduction or Yoda1 treatment was used to silence or activate Piezo1. Phalloidin staining was applied to examine the actin cytoskeleton in HeLa and SiHa cells. Transwell assays were conducted to evaluate the invasive and migratory capabilities of the cells. Dot blot and ELISA assays were performed to measure the PIP2 content on the cell membrane. Western blot or qRT-PCR was used to assess the expression levels of EMT markers, RhoA, and ROCK1.
resultsPiezo1, PIP2, and F-actin were upregulated in cervical cancer tissues, with the highest levels observed in tissues from patients with lymph node metastasis. Silencing Piezo1 downregulated the expression of F-actin and disrupted the organization of actin filaments. This cytoskeletal disruption served as an upstream event that inhibited EMT, as well as the invasion and migration of cervical cancer cells. Mechanistically, Piezo1 activated the RhoA/ROCK1 pathway, which in turn increased PIP2 levels in cervical cancer cells, leading to actin cytoskeleton remodeling in these cells.
conclusionPiezo1 drives actin cytoskeleton remodeling through the RhoA/ROCK1/PIP2 signaling pathway, thereby promoting EMT, invasion, and migration in cervical cancer. Targeting Piezo1 may offer a novel therapeutic strategy, potentially improving patient outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.